GENEVA, Switzerland — The World Health Organization has warned that global efforts to combat antimicrobial resistance remain significantly behind international targets for 2030, despite an increase in the number of countries adopting national action plans.
In findings released on November 16, the WHO reported that 173 of 183 surveyed countries had developed national plans to address antimicrobial resistance. However, only 42 countries reported having the necessary funding and implementation measures in place.
The findings highlight a major gap between government commitments and the practical measures needed to prevent drug-resistant infections, improve medical testing and ensure patients receive effective treatment.
What is antimicrobial resistance?
Antimicrobial resistance, commonly known as AMR, occurs when bacteria, viruses, fungi and parasites develop the ability to survive medicines that were previously effective against them.
Antibiotic resistance is one of the most widely recognised forms of this problem. It can make ordinary bacterial infections more difficult to treat and increase the risk of serious complications.
Resistance can develop and spread through several factors, including the inappropriate use of antibiotics, inadequate infection prevention, poor access to diagnostic testing and the spread of resistant microorganisms between people, animals and the environment.
According to the WHO, approximately one in six laboratory-confirmed bacterial infections worldwide in 2023 was resistant to antibiotics.
The growing problem could make routine medical procedures, including surgery, childbirth and cancer treatment, more difficult and potentially riskier when effective medicines are unavailable.
WHO report highlights funding problems
The WHO's latest Tracking Antimicrobial Resistance Country Self-assessment Survey examined progress across 183 countries in 2026.
The number of countries reporting national AMR action plans has increased substantially, rising from 79 in 2017 to 173 in the latest assessment.
However, the WHO warned that adopting a policy does not automatically translate into effective action.
Only 42 countries reported that their national plans were both financed and implemented, demonstrating the significant funding and delivery challenges facing governments.
The organisation has called for greater investment in infection prevention, laboratory testing, surveillance systems and access to appropriate antimicrobial medicines.
Medical testing remains a major challenge
One of the most important problems identified in the report is the limited availability of laboratory testing for drug-resistant infections.
Diagnostic testing helps healthcare professionals identify the microorganisms responsible for infections and determine which medicines are likely to work.
Without reliable testing, patients may receive antibiotics that are unnecessary or ineffective, while resistant infections can remain undetected.
The WHO reported that only 36 percent of countries had national reference laboratories equipped to test for selected bacterial and fungal resistance.
This remains considerably below the international target of 80 percent of countries having comprehensive testing capacity by 2030.
The organisation has released two practical tools to help countries improve diagnostic capacity, including guidance on essential tests and laboratory procedures for identifying bacterial and fungal infections.
Infection prevention programmes fall short
Preventing infections is another important part of reducing antimicrobial resistance.
Effective infection prevention programmes can reduce the spread of harmful microorganisms in hospitals, healthcare facilities and communities while lowering the need for antibiotics.
According to the WHO assessment, 128 countries had national infection prevention and control programmes and guidelines. However, only 69 had implemented these programmes nationwide.
This represents a significant gap compared with the international goal of achieving nationwide implementation in 90 percent of countries by 2030.
Improving hygiene, strengthening healthcare standards, supporting vaccination and ensuring appropriate infection-control practices are among the measures that can help reduce the spread of resistant infections.
Why antibiotic resistance threatens global healthcare
Antibiotics are essential medicines used to treat many bacterial infections and support modern medical procedures.
When bacteria become resistant to available treatments, infections can become more difficult to manage, potentially requiring longer hospital stays, more complex treatment and additional healthcare resources.
The threat extends beyond individual patients because resistant microorganisms can spread between communities and across international borders.
The WHO has also warned that the development of new antibiotics is not keeping pace with the spread of antimicrobial resistance.
Experts say governments, healthcare providers, pharmaceutical companies and agricultural sectors must work together to protect the effectiveness of existing medicines and support the development of new treatments.
World AMR Awareness Week calls for action
The WHO's findings were released ahead of World AMR Awareness Week, which takes place from November 18 to November 24 in 2026.
The campaign aims to increase public understanding of antimicrobial resistance and encourage practical action across human health, animal health, agriculture and environmental protection.
The 2026 campaign theme, One Health, one action: Prevent AMR now, highlights the connection between people, animals, plants and the environment.
The WHO is encouraging governments and communities to improve responsible antimicrobial use, strengthen infection prevention and expand access to quality diagnostic services.
What happens next?
Governments face increasing pressure to turn their national antimicrobial resistance strategies into funded and measurable programmes before the 2030 international targets.
Improving laboratory capacity, strengthening infection prevention and monitoring antibiotic use will be important steps in addressing the problem.
The latest WHO findings show that international awareness and policy commitments are increasing, but practical implementation remains uneven.
Without stronger investment and coordinated action, drug-resistant infections could place additional pressure on healthcare systems and make common medical treatments more difficult in the years ahead.
Sources and further reporting












